Metabolic activation of nevirapine in human liver microsomes: Dehydrogenation and inactivation of cytochrome P450 3A4

Drug Metabolism and Disposition

Volumn 37, Issue 7, 2009, Pages 1557-1562

  Wen, Bo ^a,b   Chen, Yuan ^a   Fitch, William L ^a  

^a Roche Palo Alto ^*  (United States)

^b Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; ELECTROPHILE; GLUTATHIONE; NEVIRAPINE; NUCLEOPHILE; QUINONE DERIVATIVE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEHYDROGENATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVATION; ENZYME INACTIVATION; GLUTATHIONE METABOLISM; HUMAN; LIVER MICROSOME METABOLISM; LIVER TOXICITY; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL;

BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; GLUTATHIONE; HEPATOCYTES; HUMANS; INDOLEQUINONES; MASS SPECTROMETRY; MICROSOMES, LIVER; NEVIRAPINE; OXIDATION-REDUCTION; PRODRUGS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67649410245     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024851     Document Type: Article

References (10)

1. Antunes AM, Duarte MP, Santos PP, da Costa GG, Heinze TM, Beland FA, and Marques MM (2008) Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine. Chem Res Toxicol 21:1443-1456.
2. Chen J, Mannargudi BM, Xu L, and Uetrecht J (2008) Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 21:1862-1870.
3. Erickson DA, Mather G, Trager WF, Levy RH, and Keirns JJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27:1488-1495.
4. Ernest CS 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
5. Hall DB and Macgregor TR (2007) Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites. HIV Clin Trials 8:391-399. (Pubitemid 350305213)
6. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356:135-147. (Pubitemid 46089674)
7. Pollard RB, Robinson P, and Dransfield K (1998) Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 20:1071-1092. (Pubitemid 29058411)
8. Popovic M, Caswell JL, Mannargudi B, Shenton JM, and Uetrecht JP (2006) Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Chem Res Toxicol 19:1205-1214. (Pubitemid 44454037)
9. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, and Keirns J (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27:895-901. (Pubitemid 29347589)
10. Wen B, Ma L, Nelson SD, and Zhu M (2008) High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. Anal Chem 80:1788-1799.